Tumor growth and tumor weight were significantly inhibited in LGR5‐KD‐injected tumors (Fig. 7B and C; P < 0.05), and immunohistochemical analysis showed that the LGR5‐KD group exhibited weaker expression of Ki‐67, which is a marker of proliferation (Fig. 7E), indicating that LGR5 exert oncogenic effects during epithelial ovarian cancer progression. Here, MKI67 is linked to ovarian carcinoma.